Loading...
Please wait, while we are loading the content...
Similar Documents
Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
| Content Provider | Scilit |
|---|---|
| Author | Lieuw, Kenneth |
| Copyright Year | 2017 |
| Description | Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? Kenneth Lieuw1,2 1Department of Pediatrics, Walter Reed National Military Medical Center, 2Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Hemophilia A (HA) is a common bleeding disorder caused by the deficiency of factor VIII (FVIII) with an incidence of ~1 in 5000 male births. Replacement of FVIII is necessary to prevent and treat bleeding episodes. However, with multiple new drugs in addition to old standards, choosing among the different FVIII treatment options is harder than ever. There are FVIII products that are plasma derived or recombinant, FVIII products designed to extend the half-life of FVIII, and the first single-chain FVIII product, recombinant factor VIII single chain (rFVIII-SC). As development of inhibitors to FVIII continues to be a major problem in the care of HA patients, recent studies showing lower rates of inhibitor development with plasma-derived FVIIII products versus recombinant FVIII products have made choosing among the many options now available even more complex. Although still unproven, extended half-life (EHL) products may provide the hope of decreased immunogenicity but need further testing in previously untreated patients (PUPs). This review highlights some of the differences between FVIII products currently available and hopefully assists the clinician to decide which FVIII product to choose for their patients. Keywords: hemophilia, hemophilia A, factor VIII, recombinant factor VIII single chain, extended half-life factor VIII, immunogenicity, bleeding disorder, inhibitor development |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479262/pdf https://www.dovepress.com/getfile.php?fileID=36962 |
| Ending Page | 73 |
| Page Count | 7 |
| Starting Page | 67 |
| ISSN | 11792736 |
| e-ISSN | 11792736 |
| DOI | 10.2147/jbm.s103796 |
| Journal | Journal of blood medicine |
| Volume Number | 8 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2017-06-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Journal of Blood Medicine Pediatrics and Child Health Bleeding Disorder Extended Half-life Factor Viii Factor Viii Hemophilia Hemophilia A Immunogenicity Inhibitor Development Recombinant Factor Viii Single Chain |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology |
